Concerning ITGB3, an evaluation in the reverse order, where the patients are classified depending on the tumours' ITGB3 expression, could determine if it is possible to distinguish patients who will respond to standard treatment from those who will not. The gene discussed is ITGB3; the disease is neoplasm.